Associations Between GFAP, Aβ42/40 Ratio, and Perivascular Spaces and Cognitive Domains in Vascular Cognitive Impairment.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Amyloid beta-Peptides*/blood ; Amyloid beta-Peptides*/metabolism ; Glial Fibrillary Acidic Protein*/blood ; Glial Fibrillary Acidic Protein*/metabolism ; Cognitive Dysfunction*/metabolism ; Cognitive Dysfunction*/blood ; Peptide Fragments*/blood ; Peptide Fragments*/metabolism ; Glymphatic System*/metabolism ; Glymphatic System*/pathology ; Dementia, Vascular*/blood ; Dementia, Vascular*/metabolism; Humans ; Female ; Male ; Aged ; Biomarkers/blood ; Middle Aged ; Cognition ; Magnetic Resonance Imaging

Perivascular spaces (PVS) support metabolic clearance in the brain and are increasingly recognized as key contributors to dementia pathogenesis. Plasma-based biomarkers, such as glial fibrillary acidic protein (GFAP) and the amyloid β42/40 (Aβ42/40) ratio, show promise in dementia diagnosis but remain understudied in vascular cognitive impairment (VCI). VCI, a major global cause of cognitive decline, may be more prevalent in Southeast Asia. Despite its impact, it is underdiagnosed compared to Alzheimer's, highlighting the need for early, reliable markers. This study aims to examine how these biomarkers relate to PVS burden and domain-specific cognitive outcomes in VCI. VCI was defined as global cognition as assessed by a Montreal Cognitive Assessment Score <26, along with the presence of confluent white matter hyperintensities (deep white matter hyperintensities score >2 or periventricular hyperintensities >3), and >1 lacuna. A total of 108 participants (mean age of 67.3 years, 51.9% female) were included. Multivariate ordinal regression assessed biomarker associations with PVS grade, adjusting for age and diastolic blood pressure. A Aβ42/40 ratio <0.05 and GFAP >54.1 pg/mL were used as biomarker thresholds to subgroup the participants, and the relationship between these thresholds and cognitive performance was analyzed. Elevated GFAP ( p = 0.0438) and a reduced Aβ42/40 ratio ( p < 0.01) were correlated with a higher PVS grade. In the subgroup with a low Aβ42/40 ratio, a greater PVS burden was associated with poorer executive function ( p = 0.045, β = 0.612), while in those with high GFAP levels, it was linked to more pronounced impairments in learning and memory ( p = 0.006, β = 0.375). A lower Aβ42/40 ratio and higher GFAP levels track greater PVS burden in VCI. PVS severity may be associated with domain-specific cognitive decline, highlighting the potential utility of these biomarkers in refining clinical assessments and monitoring disease progression.

Alzheimers Res Ther. 2021 Mar 27;13(1):68. (PMID: 33773595)
Arch Clin Neuropsychol. 2024 Apr 24;39(3):355-366. (PMID: 38097261)
Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18. (PMID: 24632990)
Cells. 2023 May 04;12(9):. (PMID: 37174709)
Alzheimers Dement. 2023 Apr;19(4):1117-1134. (PMID: 36574591)
Ann Clin Psychiatry. 2018 Aug;30(3):220-232. (PMID: 30028897)
Cerebrovasc Dis. 2015;39(3-4):224-31. (PMID: 25823458)
J Prev Alzheimers Dis. 2024;11(4):1093-1105. (PMID: 39044522)
Clin Geriatr Med. 2014 Aug;30(3):421-42. (PMID: 25037289)
Neurology. 2023 Jan 10;100(2):e107-e122. (PMID: 36253103)
Neurology. 2022 Feb 15;98(7):e688-e699. (PMID: 34906975)
Diagnostics (Basel). 2023 Feb 19;13(4):. (PMID: 36832271)
Nat Rev Neurol. 2020 Mar;16(3):137-153. (PMID: 32094487)
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17513-8. (PMID: 17090684)
Neurology. 2022 Apr 12;98(15):e1525-e1533. (PMID: 35022305)

Keywords: blood-based biomarkers; cerebrovascular disease; cognitive dysfunction; mild cognitive impairment; neurodegenerative diseases; perivascular spaces; vascular cognitive impairment

0 (Amyloid beta-Peptides)
0 (Glial Fibrillary Acidic Protein)
0 (Biomarkers)
0 (Peptide Fragments)
0 (GFAP protein, human)
0 (amyloid beta-protein (1-42))
0 (amyloid beta-protein (1-40))

Date Created: 20250507 Date Completed: 20250507 Latest Revision: 20250509

20250509

PMC12027347

10.3390/ijms26083541

40332019